Liraglutide’s FDA Panel For Weight Loss Is Test Of Diabetes Experience
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo looks to expand indication for its popular diabetes drug, which if approved would go up against competitors that have had trouble on the market.
You may also be interested in...
Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.
Arena Looking To Puff Up Belviq Sales With Smoking Indication
Arena’s Belviq has failed to gain much traction in the obesity market, but the biotech is hoping a smoking-cessation indication could help bolster sales.
Qsymia, Belviq Make Progress With Aetna, But Coverage Remains Long-Term Challenge
Aetna has issued a revised clinical policy bulletin that includes Qsymia and Belviq among the drugs it considers to be “medically necessary weight reduction medications” when a series of criteria are met.